Did we cover your area of interest?
Nordic Bioscience digest of the Best of 2022 publication series
In 2022, our scientific teams have once again worked incredibly hard to advance our technologies to better benefit patients in need. With more than 60 publications, we have published an average of more than 5 articles per month this year.
We have put together the best of 2022 for you from our various focal points—in no particular order. We invite you to browse and read according to your interests!
Novel treatments for idiopathic pulmonary fibrosis (IPF) are needed to combat this devastating disease.
To investigate the antifibrotic effect of novel compounds and increase the chances of success in clinical trials, blood-based biomarkers may already be introduced at early stages of development.
Read article
Conventional serum calprotectin biomarkers are often not as clinically useful as the fecal versions because the short half-life of calprotectin in blood reduces the window in which the current serum calprotectin ELISA assay can detect calprotectin dimer protein.
CPa9-HNE ELISA has emerged as a novel serum calprotectin biomarker with significant clinical potential as a biomarker for patients with IBD to monitor disease activity and neutrophil activity.
Read article
Monitoring changes in the extracellular matrix during liver fibrosis is of great interest. Biomarkers to assess fibrogenesis already exist, but biomarkers of fibrosis resolution have not been validated.
These biomarkers would be equally valuable for understanding disease progression or the mechanism of a particular intervention, and for understanding the potential induction of hepatic fibrosis resolution.
Read article
Identification of biomarkers associated with psoriatic arthritis (PsA) disease and their potential as predictors of response to treatment are unmet needs in PsA.
The aim of the study was to investigate the association of serum levels of tissue turnover biomarkers with PsA disease phenotypes and response to Guselkumab treatment.
Read article
All agree that osteoarthritis (OA) is a heterogeneous disease - drugs in development fail because there is no approved way to segregate patients to give them targeted treatment.
Endotyping is necessary to understand the pathogenesis that drives the disease in individual patients. In the APPROACH consortium, we have measured biochemical markers that reflect the pathogenesis of different tissue compartments affected by the disease.
Read article
A persistent problem remains unresolved in heart failure with preserved ejection fraction - targeted treatment for highly heterogeneous patients.
This heterogeneity can be the cause of the lack of response to treatment in clinical trials, making it difficult for trials to succeed. The field needs better actionable biomarkers capable of finding the patients most in need of treatment - and that starts with PRO-C6.
Read article
Pancreatic cancer is an extremely lethal and fibrotic cancer disease. Novel tools such as biomarkers and preclinical models that can improve understanding of tumor fibrosis biology, drug development, and disease progression are urgently needed.
In this publication, we established a pseudo-3D in vitro pancreatic CAF model in combination with clinical collagen biomarkers (PRO-C3 and PRO-C6) as a translational screening tool for antifibrotic drugs.
Read article
